Li Xu, Jin Qinglong, Zhang Hong, Jing Xue, Ding Zhongyang, Zhou Hongjie, Zhang Zetian, Yan Dongqing, Li Dongmei, Gao Pujun, Niu Junqi
Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Phase I Clinical Trials Unit, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Exp Ther Med. 2017 Mar;13(3):1169-1175. doi: 10.3892/etm.2017.4065. Epub 2017 Jan 19.
The present study aimed to assess improvements in liver stiffness determined by transient elastography and associated factors in Chinese patients with chronic hepatitis B (CHB) during long-term treatment with oral antiviral drugs. A total of 334 consecutive Chinese patients with CHB who underwent oral antiviral therapy and received at least two liver stiffness measurements (LSMs) at the First Hospital of Jilin University (Changchun, China) from December 2012 to February 2015 were enrolled in the present study. The cohort included 201 patients without liver cirrhosis (group 0) and 133 patients with liver cirrhosis (group 1). Each patient was subjected to LSM twice with an interval of 6 months. The mean initial liver stiffness values were 14.01±9.37 and 21.59±10.25 kPa for patients in group 0 and group 1, respectively (P<0.001). Multivariate analysis revealed that higher aspartate aminotransferase and lower alanine aminotransferase levels at baseline as well as higher α-fetoprotein levels at follow-up (24 weeks) were associated with a greater decline of liver stiffness in group 0. Furthermore, a higher liver stiffness at baseline and a longer course of antiviral therapy prior to the initial LSM were significantly correlated with a reduction of liver stiffness, whereas higher total bilirubin levels at follow-up contributed to increased liver stiffness in group 1. In conclusion, LSM at the beginning and the end of a 24-week observation period showed that antiviral drug therapy significantly improved in group 1, while a marked decreasing trend was also observed in group 0. In group 0, the reduction of liver stiffness was correlated with liver inflammation, whereas in group 1, it was correlated with the treatment duration prior to the initial LSM and serum levels of hepatitis B virus DNA. Furthermore, a higher liver stiffness at baseline was associated with a greater reduction of liver stiffness in each group.
本研究旨在评估中国慢性乙型肝炎(CHB)患者在口服抗病毒药物长期治疗期间,通过瞬时弹性成像测定的肝脏硬度改善情况及相关因素。2012年12月至2015年2月期间,在吉林大学第一医院(中国长春)接受口服抗病毒治疗并至少进行过两次肝脏硬度测量(LSM)的334例连续中国CHB患者纳入本研究。该队列包括201例无肝硬化患者(0组)和133例肝硬化患者(1组)。每位患者间隔6个月进行两次LSM。0组和1组患者的平均初始肝脏硬度值分别为14.01±9.37和21.59±10.25 kPa(P<0.001)。多因素分析显示,0组患者基线时较高的天冬氨酸氨基转移酶水平、较低的丙氨酸氨基转移酶水平以及随访(24周)时较高的甲胎蛋白水平与肝脏硬度更大程度的下降相关。此外,基线时较高的肝脏硬度以及初始LSM之前较长的抗病毒治疗疗程与肝脏硬度降低显著相关,而随访时较高的总胆红素水平导致1组肝脏硬度增加。总之,在24周观察期开始和结束时的LSM显示,抗病毒药物治疗使1组有显著改善,而0组也观察到明显的下降趋势。在0组,肝脏硬度的降低与肝脏炎症相关,而在1组,它与初始LSM之前的治疗持续时间和乙肝病毒DNA血清水平相关。此外,基线时较高的肝脏硬度与每组肝脏硬度更大程度的降低相关。